Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons

James W Keck; Lisa R Bulkow; Gregory A Raczniak; Susan E Negus; Carolyn L Zanis; Michael G Bruce; Philip R Spradling; Eyasu H Teshale; Brian J McMahon

doi:10.1128/CVI.00263-14

Hepatitis B virus antibody levels 7 to 9 years after booster vaccination in Alaska native persons

Clin Vaccine Immunol. 2014 Sep;21(9):1339-42. doi: 10.1128/CVI.00263-14. Epub 2014 Jul 23.

Authors

James W Keck¹, Lisa R Bulkow², Gregory A Raczniak³, Susan E Negus⁴, Carolyn L Zanis², Michael G Bruce², Philip R Spradling⁵, Eyasu H Teshale⁵, Brian J McMahon⁶

Affiliations

¹ Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA jameswkeck@gmail.com bdm9@cdc.gov.
² Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
³ Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, Georgia, USA Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA.
⁴ Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA.
⁵ Division of Viral Hepatitis, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
⁶ Arctic Investigations Program, Centers for Disease Control and Prevention, Anchorage, Alaska, USA Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA jameswkeck@gmail.com bdm9@cdc.gov.

Abstract

Hepatitis B antibody persistence was assessed in individuals who had previously received a vaccine booster. We measured hepatitis B surface antigen antibody (anti-HBs) levels 7 to 9 years post-hepatitis B booster in individuals with primary vaccination at birth. While 95 (91.3%) of 104 participants had detectable anti-HBs (minimum, 0.1 mIU/ml; maximum, 1,029 mIU/ml), only 43 (41%) had protective levels of ≥10 mIU/ml. Pre- and week 4 postbooster anti-HBs levels were significant predictors of hepatitis B immunity at follow-up (P < 0.001). Almost all participants had detectable anti-HBs 7 to 9 years after the hepatitis B vaccine booster, but less than half had levels ≥10 mIU/ml.

MeSH terms

Adolescent
Adult
Alaska
Child
Child, Preschool
Female
Hepatitis B / immunology
Hepatitis B / prevention & control*
Hepatitis B Antibodies / blood*
Hepatitis B Vaccines / administration & dosage
Hepatitis B Vaccines / immunology*
Hepatitis B virus / immunology*
Humans
Immunization, Secondary*
Infant
Infant, Newborn
Male
Population Groups
Time Factors

Substances

Hepatitis B Antibodies
Hepatitis B Vaccines